Omeros | OMER - Pre Tax Profit


Omeros reported $-65.12M in Pre-Tax Profit for its fiscal quarter ending in June of 2024.





Pre Tax Profit Change Date
Adma Biologics USD 61.59M 14.07M Dec/2025
Alnylam Pharmaceuticals USD 161.14M 77.83M Dec/2025
BioMarin Pharmaceutical USD -26.32M 324.19M Sep/2025
Cytokinetics USD -183.03M 123.15M Dec/2025
Gilead Sciences USD 3.64B 1.21B Sep/2025
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Immunic USD -21.38M 8.2M Jun/2024
Insmed USD -326.93M 41.77M Dec/2025
Knight Therapeutics CAD -1.92M 13.69M Sep/2025
MacroGenics USD -14.93M 31.75M Dec/2025
Omeros USD -65.12M 21.27M Jun/2024
Pacira USD 9.52M 11.45M Sep/2025
Pfizer USD 3.33B 290M Sep/2025
Rockwell Medical USD 343K 2.07M Jun/2024
Sangamo BioSciences USD -36.05M 12.94M Jun/2024
Sarepta Therapeutics USD -407.67M 213.63M Dec/2025
United Therapeutics USD 444M 6M Dec/2025
Vertex Pharmaceuticals USD 1.3B 15.8M Sep/2025
Xoma USD 15.98M 24.58M Jun/2024